Cargando…

The effect of afatinib in a pretreated patient with invasive mucinous adenocarcinoma of the lung harboring HER2 YVMA insertion: a case report

BACKGROUND: Invasive mucinous adenocarcinoma (IMA) is an uncommon variant of lung adenocarcinoma. The survival data and therapeutic methods for IMAs are limited. The frequency of human epidermal growth factor receptor 2 (HER2) mutations in IMAs is low, and the clinical benefit of HER2 inhibitors in...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Yueming, Huang, Hong, Xu, Meng, Fu, Zhihui, Zhang, Xiang’e, Chen, Xiaoyan, Guo, Weifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273679/ https://www.ncbi.nlm.nih.gov/pubmed/35836522 http://dx.doi.org/10.21037/tcr-22-1457

Ejemplares similares

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
por: Torigoe, Hidejiro, et al.
Publicado: (2018)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations
por: Yang, Shuo, et al.
Publicado: (2021)

Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report
por: Shan, Jianzhen, et al.
Publicado: (2020)

Afatinib as first‐line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature
por: Shi, Yuequan, et al.
Publicado: (2018)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
por: Wu, Shang-Gin, et al.
Publicado: (2020)

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
por: Chen, Dong, et al.
Publicado: (2020)

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
por: Chen, Yi-Chieh, et al.
Publicado: (2021)

Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report
por: Fang, Yueh‐Fu, et al.
Publicado: (2021)

Postoperative survival of pulmonary invasive mucinous adenocarcinoma versus non-mucinous invasive adenocarcinoma
por: Cui, Dongyu, et al.
Publicado: (2023)

Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report
por: Park, Cheol Kyu, et al.
Publicado: (2017)

The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations
por: Watanabe, Masahiro, et al.
Publicado: (2017)

Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review
por: Zhao, Lingling, et al.
Publicado: (2021)

Invasive mucinous adenocarcinoma of the lung
por: Xu, Lu, et al.
Publicado: (2019)

Efficacy of afatinib in a HER2 amplification-positive endometrioid adenocarcinoma patient– a case report
por: Zhou, Li, et al.
Publicado: (2019)

Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report
por: Long, Xiang, et al.
Publicado: (2020)

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
por: Schuler, Martin, et al.
Publicado: (2012)

Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report
por: Nie, Xin, et al.
Publicado: (2023)

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
por: Yang, Chih-Jen, et al.
Publicado: (2017)

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER2 oncogene alterations
por: Suzawa, Ken, et al.
Publicado: (2015)

Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring HER2 S310Y mutation: a case report
por: Gao, Yan, et al.
Publicado: (2018)

Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report
por: Lin, Ling, et al.
Publicado: (2019)

Invasive mucinous adenocarcinoma misdiagnosed as pneumonia: A case report
por: Yang, Yuping, et al.
Publicado: (2023)

Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
por: Xu, Huanhuan, et al.
Publicado: (2021)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023)

Acquired resistance mechanisms to afatinib in HER2‐amplified gastric cancer cells
por: Yoshioka, Takahiro, et al.
Publicado: (2019)

Gene signature driving invasive mucinous adenocarcinoma of the lung
por: Guo, Minzhe, et al.
Publicado: (2017)

Unusual lung involvements of invasive mucinous adenocarcinoma with chylothorax
por: Aoki, Ayako, et al.
Publicado: (2020)

Invasive Mucinous Adenocarcinoma of the Lung Presenting With Multiple Cavities
por: Nakamura, Shunsuke, et al.
Publicado: (2021)

Pulmonary invasive mucinous adenocarcinoma mimicking pulmonary actinomycosis
por: Zhu, Dongyi, et al.
Publicado: (2022)

Afatinib-Induced Acute Fatal Pneumonitis in Metastatic Lung Adenocarcinoma
por: Yoo, Sang Hoon, et al.
Publicado: (2016)

Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report
por: An, Ning, et al.
Publicado: (2019)

Pleomorphic Invasive Lobular Carcinoma of the Breast With Extracellular Mucin and HER2 Amplification
por: Burky, Matthew J, et al.
Publicado: (2020)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib
por: Ikeuchi, Tomoyuki, et al.
Publicado: (2019)

Concordance of Genomic Profiles in Matched Tissue and Plasma Samples From Chinese Patients With Lung Cancer
por: He, Yueming, et al.
Publicado: (2022)

Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
por: Jang, Yoon Jung, et al.
Publicado: (2021)

Simultaneous Inhibition of EGFR and HER2 via Afatinib Augments the Radiosensitivity of Nasopharyngeal Carcinoma Cells
por: Huang, Fangling, et al.
Publicado: (2019)

Efficacy of afatinib for pulmonary adenocarcinoma with leptomeningeal metastases harboring an epidermal growth factor receptor complex mutation (exon 19del+K754E): A case report
por: Ma, Chunhua, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bc0rbmoojoql3dlh23j7mtco7n